What question did this study set out to answer?

The study aims to evaluate the effectiveness and safety of eltrombopag for treating chemotherapy-induced thrombocytopenia.

June 13, 2026Hematology ReportsOpen Access

Eltrombopag for Chemotherapy-Induced Thrombocytopenia: A Multicenter Retrospective Real-World Study

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study evaluates eltrombopag for improving platelet counts in adults with solid tumors, suggesting positive outcomes.

The study aims to evaluate the effectiveness and safety of eltrombopag for treating chemotherapy-induced thrombocytopenia.
Conducted a retrospective, single-arm multicenter cohort study with 31 adults.
Tracked platelet counts and chemotherapy continuity from baseline through week 12 after eltrombopag initiation.
Recorded adverse events including bleeding and thrombosis.
Median platelet count increased from 33 to 99.5 × 10^9/L after 12 weeks.
58.1% of patients resumed chemotherapy within 3 weeks.
No major bleeding or thrombotic events occurred.

Baysal et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark